BioNTech SE (BNTX)vsMerck & Company Inc (MRK)
BNTX
BioNTech SE
$87.99
+1.07%
HEALTHCARE · Cap: $22.13B
MRK
Merck & Company Inc
$146.35
+3.85%
HEALTHCARE · Cap: $360.08B
Smart Verdict
WallStSmart Research — data-driven comparison
Merck & Company Inc generates 2412% more annual revenue ($66.57B vs $2.65B). MRK leads profitability with a 4.8% profit margin vs -63.6%. BNTX appears more attractively valued with a PEG of 0.05. MRK earns a higher WallStSmart Score of 36/100 (F).
BNTX
Avoid32
out of 100
Grade: F
MRK
Hold36
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+20.7%
Fair Value
$137.95
Current Price
$87.99
$49.96 discount
Margin of Safety
-73.7%
Fair Value
$83.64
Current Price
$146.35
$62.71 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Growing faster than its price suggests
Reasonable price relative to book value
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Mega-cap, among the largest globally
Generating 4.5B in free cash flow
Areas to Watch
Weak financial health signals
ROE of -9.5% — below average capital efficiency
Revenue declined 59.5%
Earnings declined 43.2%
Trading at 8.6x book value
ROE of 7.6% — below average capital efficiency
4.8% margin — thin
Elevated debt levels
Comparative Analysis Report
WallStSmart ResearchBull Case : BNTX
The strongest argument for BNTX centers on PEG Ratio, Price/Book, Debt/Equity. PEG of 0.05 suggests the stock is reasonably priced for its growth.
Bull Case : MRK
The strongest argument for MRK centers on Market Cap, Free Cash Flow.
Bear Case : BNTX
The primary concerns for BNTX are Piotroski F-Score, Return on Equity, Revenue Growth.
Bear Case : MRK
The primary concerns for MRK are Price/Book, Return on Equity, Profit Margin. A P/E of 115.8x leaves little room for execution misses. Thin 4.8% margins leave little buffer for downturns.
Key Dynamics to Monitor
BNTX profiles as a turnaround stock while MRK is a value play — different risk/reward profiles.
BNTX carries more volatility with a beta of 1.25 — expect wider price swings.
MRK is growing revenue faster at 5.1% — sustainability is the question.
MRK generates stronger free cash flow (4.5B), providing more financial flexibility.
Bottom Line
MRK scores higher overall (36/100 vs 32/100). BNTX offers better value entry with a 20.7% margin of safety. Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
BioNTech SE
HEALTHCARE · BIOTECHNOLOGY · USA
BioNTech SE, a biotechnology company, develops and markets immunotherapies for cancer and other infectious diseases. The company is headquartered in Mainz, Germany.
Merck & Company Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?